Marija Kosić, Zorica Nešić, Sofija Glumac, Marko Vasić, Vladislav Pajović, Bojana Savić, Nina Japundžić-Žigon
Doxorubicin (DOX) is an effective anticancer drug. However, its use is hampered by the development of very mortal cardiomyopathy. Here, we investigate whether the co-administration of the antidepressant paroxetine (P), known to exert beneficial cardiovascular effects, would provide effective cardioprotection. Experiments were performed in male Wistar rats randomly assigned to control group (0.5 mL/kg 0.9% NaCl, i.v., n = 7), DOX group (DOX 5 mg /kg i.v., n = 23) and DOX+P group (DOX 5 mg/kg, i...
January 2022: Biomedicine & Pharmacotherapy